(19) found that additional HAIC treatment was significantly associated with better treatment response and survival benefits in advanced hepatocellular carcinoma (HCC) patients treated with lenvatinib plus PD-1 inhibitors. Here, PDCD1 is linked to hepatocellular carcinoma.